Figures
Abstract
Background & Aims
IL28B polymorphisms were shown to be strongly associated with the response to interferon therapy in chronic hepatitis C (CHC) and spontaneous viral clearance. However, little is known about how these polymorphisms affect the natural course of the disease. Thus, we conducted the present meta-analysis to assess the impact of IL28B polymorphisms on disease progression.
Methods
A literature search was conducted using MEDLINE, EMBASE, and the Cochrane Library. Integrated odds ratios (OR) were calculated with a fixed-effects or random-effects model based on heterogeneity analyses.
Results
We identified 28 studies that included 10,024 patients. The pooled results indicated that the rs12979860 genotype CC was significantly associated (vs. genotype CT/TT; OR, 1.122; 95%CI, 1.003–1.254; P = 0.044), and that the rs8099917 genotype TT tended to be (vs. genotype TG/GG; OR, 1.126; 95%CI, 0.988–1.284; P = 0.076) associated, with an increased possibility of severe fibrosis. Both rs12979860 CC (vs. CT/TT; OR, 1.288; 95%CI, 1.050–1.581; P = 0.015) and rs8099917 TT (vs. TG/GG; OR, 1.324; 95%CI, 1.110–1.579; P = 0.002) were significantly associated with a higher possibility of severe inflammation activity. Rs8099917 TT was also significantly associated with a lower possibility of severe steatosis (vs. TG/GG; OR, 0.580; 95%CI, 0.351–0.959; P = 0.034), whereas rs12979860 CC was not associated with hepatic steatosis (vs. CT/TT; OR, 1.062; 95%CI, 0.415–2.717; P = 0.901).
Citation: Sato M, Kondo M, Tateishi R, Fujiwara N, Kato N, Yoshida H, et al. (2014) Impact of IL28B Genetic Variation on HCV-Induced Liver Fibrosis, Inflammation, and Steatosis: A Meta-Analysis. PLoS ONE 9(3): e91822. https://doi.org/10.1371/journal.pone.0091822
Editor: Ming-Lung Yu, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan
Received: October 3, 2013; Accepted: February 15, 2014; Published: March 17, 2014
Copyright: © 2014 Sato et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Global COE Program, “Center of Education and Research for Advanced Genome-Based Medicine: For personalized medicine and the control of worldwide infectious diseases”; the Ministry of Education, Culture, Sports, Science and Technology, Japan; by grants from the Leading Project of the Ministry of Education, Culture, Sports, Science and Technology, Japan; and by Health and Labor Sciences Research Grants for Research on Hepatitis from the Ministry of Health, Labor and Welfare, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) [1]. In epidemiological studies of chronic HCV infection, age, duration of infection, alcohol consumption, coinfection with human immune deficiency virus, low CD4 count, male gender, and HCV genotype 3 have been shown to be associated with histological activity [2]–[7]. Although these factors explain part of the extreme variability seen in the progression of fibrosis among HCV-infected patients, they do not completely account for the differences. Genetic host factors have long been suspected to play a role in chronic hepatitis C (CHC) [8]–[10]. Two genome-wide association studies recently reported the susceptible loci for the progression of liver cirrhosis [11], [12].
Currently, patients with CHC are treated with a combination of peg-interferon (peg-IFN) and ribavirin [13], [14]. Telaprevir and boceprevir, two protease inhibitors, were recently approved for patients with genotype 1 in combination with peg-IFN and ribavirin. This combination has been shown to lead to substantial improvement in the sustained virologic response rate [15], [16]. Genetic variations near the interleukin 28B (IL28B) gene, encoding type III IFN-λ3, were shown to be strongly associated with the response to peg-IFN and ribavirin treatment in patients with CHC [17]–[20] and with spontaneous clearance of HCV [21]. Host immune cells produce IFN and other cytokines in response to viral infection. In response to HCV, cellular sensors detect the double-stranded RNA via retinoic acid-inducible gene-I and toll-like receptor 3 and activate a pathway to produce antiviral cytokines, including alpha and beta IFNs that trigger an antiviral response to eradicate the virus [22], [23].
Polymorphisms of genes involved in innate immunity are likely to influence the strength and nature of this defense system [24]. Moreover, IL28B polymorphisms were shown to be associated with lipid metabolism [25]. Thus, this genetic factor is thought to influence the natural course of HCV infection including liver fibrosis, inflammation activity, or steatosis. However, associations between IL28B polymorphisms and the state of background liver disease (fibrosis, inflammation activity, or steatosis) in patients with CHC remain controversial. Single studies may have limited statistical power to detect the modest effects of IL28B polymorphisms on disease progression.
Thus, we conducted the present meta-analysis to integrate the results of eligible studies and provide statistically reliable evidence of the role of IL28B polymorphisms in patients with CHC.
Materials and Methods
2.1 Search strategy
An electronic search was conducted in MEDLINE, EMBASE, and the Cochrane Library for articles published prior to 30 April, 2012. Search terms included IL28B, IL28, IL-28B, interleukin-28B, interleukin 28B, rs12979860, and rs8099917. The search was limited to the English language.
2.2 Inclusion criteria
A study was included in the current analysis if it satisfied the following criteria: (1) It evaluated the associations between IL28B polymorphisms (rs12979860 or rs8099917) and liver fibrosis, inflammation activity, or steatosis. We also included studies that evaluated fibrosis or inflammation activity using the aminotransferase platelet ratio index or ALT. (2) It provided sufficient published data for estimating odds ratios (OR) with 95% confidence intervals (CIs). In case of multiple studies based on the same population, we selected the study with the largest number of participants. A study was excluded if (1) it dealt only with co-infection of HCV and human immunodeficiency virus, (2) it dealt only with patients with a specific condition such as a comorbid disease (e.g., thalassemia) or status after liver transplantation, or (3) it only used a recessive hereditary model (rs12979860 CC + CT vs. TT, or rs8099917 TT +TG vs. GG).
2.3 Data extraction
Two authors (M.S. and M.K.) independently screened titles and abstracts for potential eligibility and full texts for final eligibility. Disagreements were resolved by consultation with a third author (R.T.). The following information was extracted or calculated from each study: first author, year of publication, country of origin, ethnicity, sex, HCV genotype, and background liver information (fibrosis, inflammation activity, or steatosis) for each genotype. The analysis was based on the dominant model (CC vs. CT and TT in rs12979860; TT vs. TG and GG in rs8099917).
2.4 Definition
In some studies, mild or severe fibrosis or inflammation activity was not defined. To compare results among studies on these outcomes, we defined Ishak level F4 to F6; METAVIR, Ludwig Batts, and Inuyama level F3 to F4; and Knodell histology activity index as severe fibrosis. We also defined METAVIR A2 to A3 as severe inflammation activity.
2.5 Statistical analysis
The association of liver fibrosis, inflammation activity, or steatosis with the IL28B genotype in patients with CHC was assessed by summary ORs and corresponding 95% CIs. Heterogeneity among studies was examined with I2 statistics interpreted as the proportion of total variation contributed by between-study variation [26]. If there was no or low statistical heterogeneity among studies (I2<50% and P>0.05), the ORs and 95% CIs were calculated by the fixed-effects model. Otherwise, the random-effects model was adopted. When significant heterogeneity was observed, we performed a meta-regression analysis to investigate relationships between the effect of IL28B polymorphisms on liver fibrosis, inflammation activity, or steatosis; and continuous variables (proportion of patients with genotype 1 or 4 virus infection, proportion of males; and proportion of Caucasian, African-American, and Asian patients) to explore the possible reason for heterogeneity between studies [27], [28]. To check for publication bias, we used the linear regression approach described by Egger et al. [29]. All calculations were performed using Comprehensive Meta-Analysis software (Biostat, Englewood, NJ).
Results
3.1 Characteristics of articles
Figure 1 shows the literature search and study selection procedures. A total of 471 potentially relevant publications up to 30 April, 2012, were initially identified through MEDLINE, EMBASE, and the Cochrane Library, 443 of which were excluded because they did not meet our inclusion criteria. Therefore, 28 studies involving a total number of 10,024 patients were included in the meta-analysis. Study characteristics are shown in Table 1. There were 5616 males and 3974 females, and the sex was not reported in the remaining 434 patients (1 study). Nineteen studies (7542 patients) evaluated liver fibrosis according to rs12979860 polymorphism and 16 studies (5052 patients) according to rs8099917 polymorphism; four studies (2301 patients) evaluated inflammation activity according to rs12979860 polymorphism and eight studies (2904 patients) according to rs8099917 polymorphism; and four studies (962 patients) evaluated steatosis according to rs12979860 polymorphism and five studies (1308 patients) according to rs8099917 polymorphism.
Twenty-eight individual studies that met all of the inclusion and exclusion criteria.
3.2 Fibrosis
For rs12979860, the between-study heterogeneity was not significant (I2 = 25%, P = 0.147); thus, the fixed-effects model was applied. The pooled results indicated that IL28B rs12979860 genotype CC was associated with an increased possibility of severe fibrosis (OR, 1.122; 95%CI, 1.003–1.254; P = 0.044) (Fig. 2-a). For rs8099917, there was no or low heterogeneity (I2 = 31%, P = 0.111), and IL28B rs8099917 genotype TT tended to be associated with a higher possibility of severe fibrosis; however, the difference did not reach statistical significance (OR, 1.126; 95%CI, 0.988–1.284; P = 0.076) (Fig. 2-b). Egger's test showed no evidence for publication biases for either rs12979860 (P = 0.839) or rs8099917 (P = 0.342). When restricted to studies in which only treatment-naïve patients were included, 12 studies (5865 patients) according to rs12979860 polymorphism and eight studies (3333 patients) according to rs8099917 polymorphism were extracted. The between-study heterogeneities were not significant for rs12979860 (I2 = 0%, P = 0.615) and rs8099917 (I2 = 16%, P = 0.304). For rs12979860, fixed-effect model analyses showed a higher probability of severe fibrosis in genotype CC (OR, 1.184; 95%CI, 1.040–1.348; P = 0.010) (Fig. 2-c), and for rs8099917, genotype TT tended to be associated with a higher possibility of severe fibrosis; however, the difference was not statistically significant (OR, 1.154; 95%CI, 0.985–1.351; P = 0.076) (Fig. 2-d). Egger's test showed no evidence of publication bias (P = 0.394 for rs12979860 and P = 0.295 for rs8099917).
(a) rs12979860 in all patients, (b) rs8099917 in all patients, (c) rs12979860 in treatment-naïve patients, and (d) rs8099917 in treatment-naïve patients.
3.3 Inflammation activity
The between-study heterogeneity was not significant (I2 = 35%, P = 0.204) for rs12979860. In the fixed-effects model, the pooled results indicated that IL28B rs12979860 genotype CC was associated with a higher possibility of severe inflammation activity (OR, 1.288; 95%CI, 1.050–1.581; P = 0.015) (Fig. 3-a). For rs8099917, there was no or low heterogeneity (I2 = 0%, P = 0.598), and IL28B rs8099917 genotype TT was also associated with a higher possibility of severe inflammation activity (OR, 1.324; 95%CI, 1.110–1.579; P = 0.002) (Fig. 3-b). Egger's test showed no evidence of publication biases for rs12979860 (P = 0.448) and rs8099917 (P = 0.531). When restricted to studies in which only treatment-naïve patients were included, three studies (2192 patients) according to rs12979860 polymorphism and two studies (1769 patients) according to rs8099917 polymorphism were extracted. Significant heterogeneities were found for rs12979860 (I2 = 53%, P = 0.120); thus, the random-effect model was applied. The pooled results indicated that IL28B rs12979860 genotype was not associated with inflammatory activity (OR, 1.340; 95%CI, 0.938–1.916; P = 0.108) (Fig. 3-c). For rs8099917, the between-study heterogeneity was not significant (I2 = 0%, P = 0.585). In the fixed-effects model, genotype TT tended to be associated with a higher possibility of severe inflammation activity (OR, 1.217; 95%CI, 0.978–1.515; P = 0.079) (Fig. 3-d). Egger's test showed no evidence of publication bias in rs12979860 (P = 0.646). For rs8099917, Egger's test was not applicable because only 2 studies were included. We also performed a meta-regression analysis for rs12979860 because significant heterogeneities were observed. Table 2 shows the results of these meta-regression analyses. Significant correlation was observed between rs12979860 polymorphisms and the proportion of patients with genotype 1 or 4 virus (slope, 2.992±1.497; P = 0.046).
(a) rs12979860 and (b) rs8099917. (c) rs12979860 in treatment-naïve patients, and (d) rs8099917 in treatment-naïve patients.
3.4 Steatosis
Significant heterogeneities were found for rs12979860 (I2 = 86%, P<0.001) and rs8099917 (I2 = 52%, P = 0.082); thus, we applied the random-effects model for this outcome. The pooled results indicated that IL28B rs12979860 genotype CC was not associated with hepatic steatosis (OR, 1.062; 95%CI, 0.415–2.717, P = 0.901) (Fig. 4-a), whereas rs8099917 TT was significantly associated with a lower possibility of severe steatosis (OR, 0.580; 95%CI, 0.351–0.959; P = 0.034) (Fig. 4-b). Egger's test showed no evidence of publication biases for rs12979860 (P = 0.238) or rs8099917 (P = 0.182). We also performed a meta-regression analysis because significant heterogeneities were observed. Table 3 shows the results of these meta-regression analyses. In terms of the effect of rs12979860 on steatosis, significant correlations were observed between the proportion of patients with genotype 1 or 4 virus (slope, −4.947±1.086; P<0.001), the proportion of Caucasian patients (slope, 7.361±1.569; P<0.001), and the proportion of African-American patients (slope, −8.996±1.918; P<0.001). We also observed a significant correlation between the effect of rs8099917 polymorphism on steatosis and the proportion of male patients (slope, 6.225±2.530; P = 0.014) (Fig. 5). Finally, we observed significant correlations between rs8099917 polymorphisms and the proportion of patients with genotype 1 or 4 virus (slope, −2.704±1.277; P = 0.034), the proportion of Caucasian patients (slope, 1.168±0.422; P = 0.006), and the proportion of Asian patients (slope, −1.049±0.398; P = 0.008). When restricted to studies in which only treatment-naïve patients were included, two studies (495 patients) according to rs12979860 polymorphism and four studies (812 patients) according to rs8099917 polymorphism were extracted. The between-study heterogeneities were not significant for rs12979860 (I2 = 0%, P = 0.823) and rs8099917 (I2 = 41%, P = 0.166). For rs12979860, fixed-effect model analyses showed that rs12979860 genotype CC was significantly associated with a higher possibility of severe steatosis (OR, 1.708; 95%CI, 1.047–2.787; P = 0.032) (Fig. 4-c), whereas rs8099917 TT was significantly associated with a lower possibility of severe steatosis (OR, 0.675; 95%CI, 0.474–0.960; P = 0.026) (Fig. 4-d). Egger's test showed no evidence of publication bias in rs8099917 (P = 0.554). For rs12979860, Egger's test was not applicable because only 2 studies were included.
(a) rs12979860 and (b) rs8099917. (c) rs12979860 in treatment-naïve patients, and (d) rs8099917 in treatment-naïve patients.
Discussion
In the present study, we evaluated the association between IL28B polymorphisms and the background liver disease (fibrosis, inflammation activity, or steatosis) in patients with CHC. The rs12979860 CC genotype was significantly associated with a higher probability of severe fibrosis (Fig. 2-c), and the rs8099917 TT genotype tended to be associated with a higher possibility of severe fibrosis (Fig. 2-d). The accumulation of liver inflammation promotes liver fibrosis, and these polymorphisms are associated with the effect of IFN-based treatment; therefore, past treatment might alter the results. Thus, we also analyzed studies involving only patients without a history of IFN-based treatment; however, the results were not changed.
The rs12979860 CC and rs8099917 TT genotypes were also associated with a higher possibility of severe inflammation activity. Genetic variations near the IL28B gene were originally reported as strong predictors of a sustained viral response [17]–[20] or spontaneous clearance of HCV [21]. The level of IL28B gene transcripts is reportedly higher in patients homozygous for the IFN responsive allele [18], [19]. Therefore, in patients with the rs12979860 CC and rs8099917 TT genotype, IL28B production, which induces expression of interferon-stimulated genes, including some inflammatory cytokines, was thought to be increased. This may be the underlying cause of the higher inflammation activity and progressed fibrosis in patients with the IFN responsive allele. In analysis with the studies involving only patients without a history of IFN-based treatment, rs12979860 CC and rs8099917 TT genotypes were associated with higher possibility of having severe inflammation activity; however, the differences did not reach to the significant level. Only three studies according to rs12979860 polymorphism and two studies according to rs8099917 polymorphism were included when restricted to studies with only treatment-naïve patients, and may be underpowered to detect the effects of IL28B polymorphisms on inflammation activity. The further analyses with larger sample are needed to confirm this association. Additionally, meta-regression analysis showed that the effect of the rs12979860 polymorphism was influenced by viral genotype distribution. This result may imply a different influence of rs12979860 polymorphism on immune response according to viral genotype in treatment-naïve patients.
IL28B polymorphisms were also shown to be associated with lipid metabolism [25]. In the present study, the rs8099917 TT genotype was significantly associated with a lower possibility of severe steatosis. This association still remained statistically significant after we restricted to studies in which only treatment-naïve patients were included. The lower hepatic steatosis in patients with the IFN responsive allele could be explained by a more efficient export of lipids from hepatocytes. Higher interferon expression was shown to lead to suppression of lipoprotein lipase, which would result in decreased conversion of VLDL to LDL and subsequent higher steatosis [30]–[33]. The difference in IL28B expression might cause an aberration of lipid metabolism in patients with CHC. We found no significant association of rs12979860 with steatosis. And when we restricted to treatment-naïve patients, rs12979860 CC genotype was significantly associated with a higher possibility of severe steatosis. Previous studies have shown that racial differences or viral genotypes make a difference in the effects of rs12979860 and rs8099917 polymorphisms [34], [35]. This may explain the discrepancy between the effect of rs12979860 and rs8099917 on hepatic steatosis. However, only four studies (962 patients) were included in the analysis of rs12979860; or when it comes to the studies with only treatment-naïve patients, only two studies (495 patients) were extracted. Thus, we should not make any definite conclusion on this matter right now. Further studies with larger sample sizes are needed to identify their exact correlation.
According to the meta-regression analysis, the effect of rs8099917 polymorphisms on steatosis became smaller with the increase in the male proportion (Fig. 5), suggesting that a sexual dimorphism might be involved in the effect of rs8099917 polymorphisms on the liver fat content. Although the present study cannot explain the interaction between the polymorphism and sex, immune systems responding to IFN are reportedly controlled by estrogenic sex hormones [36], [37]. Differences in IL28B expression mediated by sex hormones could be a possible mechanism for the sexual dimorphism in the effect of rs8099917 polymorphisms on liver steatosis.
The rs738409 genotype within the patatin-like phospholipase domain containing 3 locus was also reported to be associated with hepatic steatosis in patients with CHC [38]–[40]. Notably, previous meta-analysis evaluating the effect of patatin-like phospholipase domain containing 3 polymorphisms on steatosis also reported a negative correlation between the male proportion and the effect of rs738409 on the liver fat content in nonalcoholic fatty liver disease [41]. Interestingly, the meta-regression analysis in the present study showed that the effect of the IL28B (rs12979860 and rs8099917) polymorphisms on steatosis was also influenced by racial and viral genotype distributions.
In the present study, we included studies that did not report the associations between IL28B genotypes and background liver diseases as study outcomes, but provided raw data that allowed us to calculate the OR for each outcome, which may have minimized potential publication bias. In fact, no publication bias was observed in the present study. The Human Genome Epidemiology Network highlighted the necessity of meta-analysis before evidence for a particular association can be regarded as strong [42]. The impact of IL28B genotypes on the disease progression found in the present meta-analysis may provide clinically important information in the follow-up of patients with CHC. The effect of IL28B polymorphisms on hepatocarcinogenesis, which is also crucial information in the HCC screening of patients with CHC, remains controversial [43]–[47]. Further analysis with larger sample sizes may be needed to elucidate the exact effect of IL28B polymorphisms on hepatocarcinogenesis.
A potential limitation of this study is inter-study variability in the outcome measure and the definition of “severe” among studies, where some discrepancies among studies exist. The studies without a pathological diagnosis, using laboratory data as surrogates, were also included. These studies may have diminished the accuracy of our research results concerning liver disease severity.
In conclusion, the present study highlighted the impact of IL28B polymorphisms on liver fibrosis, inflammation activity, and steatosis in patients with CHC. Disease progression appeared to be promoted in patients with rs12979860 CC or rs8099917 TT genotypes. The current findings may provide clinically important information in the follow-up of patients with CHC.
Acknowledgments
The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see:
Author Contributions
Conceived and designed the experiments: MS RT NK. Performed the experiments: MS MK RT. Analyzed the data: MS RT. Contributed reagents/materials/analysis tools: MS. Wrote the paper: MS RT HY. Critical revision of manuscript: NF MT KK.
References
- 1. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, et al. (1995) Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 21: 639–644.
- 2. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825–832.
- 3. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, et al. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29: 1215–1219.
- 4. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, et al. (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31: 828–833.
- 5. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, et al. (2006) Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 44: S19–24.
- 6. Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, et al. (2009) Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 51: 655–666.
- 7. De Nicola S, Aghemo A, Rumi MG, Colombo M (2009) HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. J Hepatol 51: 964–966.
- 8. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC (1999) Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 354: 2119–2124.
- 9. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, et al. (2007) Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 14: 556–563.
- 10. Kato N, Ji G, Wang Y, Baba M, Hoshida Y, et al. (2005) Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology 42: 846–853.
- 11. Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, et al. (2013) A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol; 58 (5): 875–82.
- 12. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, et al. (2012) Genome-Wide Association Study Identifies Variants Associated with Progression of Liver Fibrosis from HCV Infection. Gastroenterology; 143 (5): 1244–52.
- 13. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355.
- 14. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965.
- 15. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, et al. (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360: 1827–1838.
- 16. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195–1206.
- 17. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399–401.
- 18. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105–1109.
- 19. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100–1104.
- 20.
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al.. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: : 1338–1345, 1345 e1331–1337.
- 21. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798–801.
- 22. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730–737.
- 23. Moriyama M, Kato N, Otsuka M, Shao RX, Taniguchi H, et al. (2007) Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A. Hepatol Int 1: 302–310.
- 24. Li CZ, Kato N, Chang JH, Muroyama R, Shao RX, et al. (2009) Polymorphism of OAS-1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver Int 29: 1413–1421.
- 25. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, et al. (2010) Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51: 1904–1911.
- 26.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2009) Introduction to Meta-analysis. West Sussex: John Wiley & Sons Ltd.
- 27. Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 63: 1426–1434.
- 28. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18: 2693–2708.
- 29. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
- 30. Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH (1992) The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 12: 1053–1062.
- 31. Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, et al. (1982) Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 2: 68–73.
- 32. Shinohara E, Yamashita S, Kihara S, Hirano K, Ishigami M, et al. (1997) Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 25: 1502–1506.
- 33. Andrade RJ, Garcia-Escano MD, Valdivielso P, Alcantara R, Sanchez-Chaparro MA, et al. (2000) Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. Aliment Pharmacol Ther 14: 929–935.
- 34. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, et al. (2011) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54: 415–421.
- 35. Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, et al. (2011) Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol; 55 (6): 1195–200.
- 36. Nakaya M, Tachibana H, Yamada K (2006) Effect of estrogens on the interferon-gamma producing cell population of mouse splenocytes. Biosci Biotechnol Biochem 70: 47–53.
- 37. Siracusa MC, Overstreet MG, Housseau F, Scott AL, Klein SL (2008) 17beta-estradiol alters the activity of conventional and IFN-producing killer dendritic cells. J Immunol 180: 1423–1431.
- 38.
Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, et al.. (2011) Viral Genotype-Specific Role of PNPLA3, PPARG, MTTP and IL28B in Hepatitis C Virus-Associated Steatosis. J Hepatol.
- 39. Trepo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, et al. (2011) Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54: 60–69.
- 40. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, et al. (2011) Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53: 791–799.
- 41. Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53: 1883–1894.
- 42. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, et al. (2008) Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 37: 120–132.
- 43. Asahina Y, Tanaka K, Suzuki Y, Tamaki N, Hoshioka T, et al. (2011) Association between IL28B gene variation and development of hepatocellular carcinoma after interferon therapy in patients with chronic hepatitis c. Journal of Hepatology 54: S37.
- 44. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, et al. (2011) IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 54: 716–722.
- 45. Joshita S, Umemura T, Katsuyama Y, Ichikawa Y, Kimura T, et al. (2011) Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum Immunol; 73 (3): 298–300.
- 46.
Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, et al.. (2011) Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int; Aug 17 [Epub ahead of print].
- 47. Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, et al. (2011) IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology; 55 (2): 384–94.
- 48. Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, et al. (2010) Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 53: 439–443.
- 49. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 139: 499–509.
- 50.
Lotrich FE, Loftis JM, Ferrell RE, Rabinovitz M, Hauser P (2010) IL28B Polymorphism Is Associated with Both Side Effects and Clearance of Hepatitis C During Interferon-Alpha Therapy. J Interferon Cytokine Res; Dec 6 [Epub ahead of print].
- 51. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, et al. (2010) Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52: 33–37.
- 52.
Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al.. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: : 120–129 e118.
- 53. Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, et al. (2011) IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol; 55 (5): 980–8.
- 54. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140: 1021–1031.
- 55. Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, et al. (2011) Role of Interleukin 28B rs12979860 C/T Polymorphism on the Histological Outcome of Chronic Hepatitis C: Relationship with Gender and Viral Genotype. J Clin Immunol; 31 (5): 891–9.
- 56. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, et al. (2011) Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 54: 439–448.
- 57. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, et al. (2011) Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 6: e17232.
- 58. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, et al. (2011) IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 6: e18322.
- 59. Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, et al. (2011) IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat 18: e325–331.
- 60. Lindh M, Lagging M, Farkkila M, Langeland N, Morch K, et al. (2011) Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 203: 1748–1752.
- 61. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, et al. (2011) Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54: 1127–1134.
- 62. Miyamura T, Kanda T, Nakamoto S, Wu S, Fujiwara K, et al. (2011) Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS ONE; 6 (12): e28617.
- 63. Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, et al. (2011) IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53: 746–754.
- 64.
de Rueda PM, Lopez-Nevot MA, Saenz-Lopez P, Casado J, Martin-Casares A, et al.. (2011) Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin. Am J Gastroenterol.
- 65. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, et al. (2011) Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53: 7–13.
- 66.
Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, et al.. (2011) Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response. Hepatology.
- 67. Mach T, Ciesla A, Sanak M, Golwacki M, Warunek W, et al. (2012) The importance of IL28B polymorphism in response to pegylated interferon (alpha) and ribavirin in chronic hepatitis caused by HCV genotype 1b. Przeglad Gastroenterologiczny 7: 38–42.
- 68. Miyashita M, Ito T, Sakaki M, Kajiwara A, Nozawa H, et al. (2012) Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat 19: 608–614.
- 69. Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, et al. (2012) IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol 47: 834–844.
- 70. Rembeck K, Alsio A, Christensen PB, Farkkila M, Langeland N, et al. (2012) Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One 7: e29370.
- 71.
Tolmane I, Rozentale B, Keiss J, Ivancenko L, Subnikova N, et al.. (2012) Interleukin 28B Gene Polymorphism and Association with Chronic Hepatitis C Therapy Results in Latvia. Hepat Res Treat: 324090.
- 72. Toyoda H, Kumada T, Tada T, Hayashi K, Honda T, et al. (2012) Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b. J Med Virol 84: 61–70.